Docetaxel （Beihai）
Tier C — Watch / tradeDocetaxel （Beihai）
Targets：Tubulin
Brand：BEIZRAY
Indications (approved)：Non-small cell lung cancer, Prostate cancer, Castration-resistant prostate cancer, Breast cancer, Head and neck cancer, Head and neck squamous cell carcinoma, Gastric cancer
Regional status
Factories producing this API1
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
1 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates
Frequently asked questions
What are the approved indications of Docetaxel （Beihai）?
Approved indications include: Non-small cell lung cancer, Prostate cancer, Castration-resistant prostate cancer, Breast cancer, Head and neck cancer, Head and neck squamous cell carcinoma, Gastric cancer.
When does the Docetaxel （Beihai） patent expire?
No public expiry year is available for Docetaxel （Beihai） yet; this page updates once verified.
How do I get a quote for Docetaxel （Beihai） intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27